High Immunogenic Cuproptosis Evoked by In Situ Sulfidation-Activated Pyroptosis for Tumor-Targeted Immunotherapy of Colorectal Cancer

原位硫化激活的细胞焦亡诱导的高免疫原性铜凋亡用于结直肠癌肿瘤靶向免疫治疗

阅读:1

Abstract

Despite the great potential of cuproptosis in tumor therapy, the current cuproptosis-based therapy still suffers from compromised efficiency of immune activation. Pyroptosis, a proinflammatory cell death modality, provides a good opportunity to induce immunogenic cell death (ICD) and promote systemic immune response. However, the synergistic cuproptosis and pyroptosis therapy has not been fully explored. Herein, it is discovered that Cu(II)-based metal-organic framework (MOF) nanoparticles (NPs) can synergistically induce cuproptosis and pyroptosis to evoke ICD for high-efficiency tumor-targeted immunotherapy. Although MOF-199 has been widely used in tumor therapy, the immunogenicity is still unclear. Pluronic F127-modified MOF-199 NPs ((F127)MOF-199 NPs) show dual-responsiveness to glutathione (GSH) and hydrogen sulfide (H(2)S). Once entering cancer cells, (F127)MOF-199 NPs dissociate in GSH-enriched tumor microenvironment (TME) to release copper ion and induce copper-overload-mediated cuproptosis. Meanwhile, (F127)MOF-199 NPs transform to Cu(2-x) S NPs by in situ sulfidation under H(2)S-enriched colorectal cancer (CRC) TME. Under photothermal and chemodynamic therapy (PTT/CDT) of Cu(2-x) S NPs, caspase-3 is activated and gasdermin E (GSDME)-related pyroptosis is triggered. The synergistic cuproptosis and pyroptosis have proved the superior antitumor immunity effect in both in vitro and in vivo experiments. This work provides a new strategy to achieve tumor-targeted immunotherapy with high efficiency by simple (F127)MOF-199 NPs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。